Fig. 1From: Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trialsPatient disposition. CM, chronic migraine; EM, episodic migraine; MAMD, monthly average migraine days. aFor participants with EM, response was defined as a reduction of ≥2 MAMD. bFor participants with CM, response was defined as a reduction of ≥4 MAMDBack to article page